GT Biopharma, Inc. GTBP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 200.61% | 192.32% | 130.17% | 19.63% | -45.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.22% | 47.41% | 48.68% | -6.16% | -61.26% |
| Operating Income | -198.22% | -47.41% | -48.68% | 6.16% | 61.26% |
| Income Before Tax | 85.02% | -265.08% | -510.09% | 8.71% | -713.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 85.02% | -265.08% | -510.09% | 8.71% | -713.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.02% | -265.08% | -510.09% | 8.71% | -713.18% |
| EBIT | -198.22% | -47.41% | -48.68% | 6.16% | 61.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 98.92% | 66.38% | -33.16% | 45.84% | -403.67% |
| Normalized Basic EPS | 98.93% | 87.63% | -6.15% | 48.27% | -402.11% |
| EPS Diluted | 98.92% | 66.38% | -33.16% | 45.84% | -403.67% |
| Normalized Diluted EPS | 98.93% | 87.63% | -6.15% | 48.27% | -402.11% |
| Average Basic Shares Outstanding | 1,300.18% | 1,191.36% | 474.86% | 76.29% | 61.90% |
| Average Diluted Shares Outstanding | 1,300.18% | 1,191.36% | 474.86% | 76.29% | 61.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |